Potential side effects of androgen deprivation treatment in sex offenders

Journal of the American Academy of Psychiatry and the Law

Volumn 37, Issue 1, 2009, Pages 53-58

  Giltay, Erik J ^a   Gooren, Louis J G ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BUSERELIN; CALCIUM; CYPROTERONE ACETATE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PAMIDRONIC ACID; PSYCHOTROPIC AGENT; RALOXIFENE; RISEDRONIC ACID; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TRIPTORELIN; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; BODY WEIGHT; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INHIBITION; DYSLIPIDEMIA; EMOTIONAL DISORDER; FATIGUE; FRACTURE; GLUCOSE METABOLISM; HEART DEATH; HEART INFARCTION; HOT FLUSH; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MALAISE; METABOLIC SYNDROME X; MOOD DISORDER; MORBIDITY; NAUSEA; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEXUAL CRIME; SIDE EFFECT; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; ADULT; COST BENEFIT ANALYSIS; DECISION MAKING; MALE; NOTE; PRISONER; SEXUAL DEVIATION;

ADULT; ANDROGEN ANTAGONISTS; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; MALE; METABOLIC SYNDROME X; MOOD DISORDERS; OSTEOPOROSIS; PARAPHILIAS; PRISONERS; SEX OFFENSES;

EID: 66149087726     PISSN: 10936793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Bancroft J: The endocrinology of sexual arousal. J Endocrinol 186:411-27,2005
2. Schmidt PJ, Berlin KL, Danaceau MA, et al.: The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry 61:997-1004, 2004
3. Gijs L, Gooren L: Hormonal and psychopharmacological interventions in the treatment of paraphilias: an update. J Sex Res 33:273-90, 1996
4. Rosier A, Witztum E: Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 338:416-22, 1998
5. Briken P, Hill A, Berner W: Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J Clin Psychiatry 64:890-7, 2003
6. Saleh FM, Guidry LL: Psychosocial and biological treatment considerations for the paraphilic and nonparaphilic sex offender. J Am Acad Psychiatry Law 31:486-93, 2003
7. Studer LH, Aylwin AS, Reddon JR: Testosterone, sexual offense recidivism, and treatment effect among adult male sex offenders. Sex Abuse 17:171-81, 2005
8. Kaufman JM, Vermeulen A: The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833-76, 2005
9. Hanson RK, Gordon A, Harris AJ, et al.: First report of the collaborative outcome data project on the effectiveness of psychological treatment for sex offenders. Sex Abuse 14:169 -94; discussion 195-7, 2002
10. Meyer WJ 3rd, Cole C, Emory E: Depo provera treatment for sex offending behavior: an evaluation of outcome. Bull Am Acad Psychiatry Law 20:249-59, 1992
11. Krueger RB, Kaplan MS: Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases. Arch Sex Behav 30:409-22, 2001
12. Grasswick LJ, Bradford JM: Osteoporosis associated witii the treatment of paraphilias: a clinical review of seven case reports. J Forensic Sci 48:849-55, 2003
13. Smith CM: Origin and uses of primum non nocere: above all, do no harm! J Clin Pharmacol 45:371-7, 2005
14. Rochira V, Granata AR, Madeo B, et al.: Estrogens in males: what have we learned in the last 10 years? Asian J Androl 7:3-20, 2005
15. Mittan D, Lee S, Miller E, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656-61, 2002
16. Greenspan SL, Coates P, Sereika SM, et al.: Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410-7, 2005
17. NishiyamaT, Ishizaki F, AnrakuT, et al.: The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90:657-60, 2005
18. Smith JC, Bennett S, Evans LM, et al.: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. ] Clin Endocrinol Metab 86:4261-7, 2001
19. Stepan JJ, Lachman M, Zverina J, et al.: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69:523-7, 1989
20. Hatano T, Oishi Y, Furuta A, et al.: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449-52, 2000
21. Shahinian VB, Kuo YF, Freeman JL, et al.: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154-64,2005
22. Walsh PC: Risk of fracture after androgen deprivation for prostate cancer. J Urol 174:929-30, 2005
23. Smith MR: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60:79-85; discussion 86, 2002
24. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 294:238-44, 2005
25. Morabito N, Gaudio A, Lasco A, et al.: Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 19:1766-70, 2004
26. Michaelson MD, Smith MR: Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23:8219-24, 2005
27. Saad F: Zoledronic acid: past, present and future roles in cancer treatment. Future Oncol 1:149-59, 2005
28. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-10, 2000
29. Ringe JD, Dorst A, Faber H, Ibach K: Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110-3, 2004
30. Moyad MA: Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/ orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology 59:34-40, 2002
31. Smith MR, Fallon MA, Lee H, et al.: Raloxifene to prevent gona-dotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841-6, 2004
32. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-56, 2006
33. Basaria S, Muller DC, Carducci MA, et al.: Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 106:581-8, 2005
34. Smith RM, Lee H, Nathan DM: Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305-8, 2006
35. Chen KC, Peng CC, Hsieh HM, et al.: Antiandrogenic therapy can cause coronary arterial disease. Int J Urol 12:886-91, 2005
36. Stellato RK, Feldman HA, Hamdy O, et al.: Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23:490-4, 2000
37. Oh JY, Barrett-Connor E, Wedick NM, et al.: Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 25:55-60,2002
38. Svartberg J, Jenssen T, Sundsfjord J, et al.: The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromso Study. Diabetes Metab 30:29-34, 2004
39. Laaksonen DE, Niskanen L, Punnonen K, et al.: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-41,2004
40. Haffner SM, Karhapaa P, Mykkanen L, et al.: Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 43: 212-9, 1994
41. Birkeland KI, Hanssen KF, Torjesen PA, et al.: Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 76: 275-8, 1993
42. Pitteloud N, Mootha VK, Dwyer AA, et al.: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28:1636-42, 2005
43. Inaba M, Otani Y, Nishimura K, et al.: Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 54:55-9, 2005
44. WHO (World Health Organization). Diet, nutrition and the prevention of chronic diseases. Report of a Joint WHO/FAO Expert Consultation. Technical report series 916. Geneva: WHO, 2003
45. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-96, 2004
46. Solomon CG: Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 348:457-9, 2003
47. Seidman SN: Testosterone deficiency and mood in aging men: pathogenic and therapeutic interactions. World J Biol Psychiatry 4:14-20,2003
48. Seidman SN: Normative hypogonadism and depression: does 'an-dropause' exist? Int J Impot Res 2006
49. Shahinian VB, Kuo YF, Freeman JL, et al.: Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166:465-71, 2006
50. Neumann F, Kalmus J: Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Exp Clin Endocrinol 98:71-80, 1991
51. Dunsieth NW Jr, Nelson EB, Brusman-Lovins LA, et al.: Psychiatric and legal features of 113 men convicted of sexual offenses. J Clin Psychiatry 65:293-300, 2004
52. Loprinzi CL, Michalak JC, Quella SK, et al.: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347-52, 1994
53. Choo R, Chander S, Danjoux C, et al.: How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol 12:2547-52, 2005
54. Giltay EJ, Gooren LJ: Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 85:2913-21, 2000
55. Bradford JM: The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatry 46:26-34, 2001
56. Kelleher S, Conway AJ, Handelsman DJ: Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89:3813-7, 2004